

DETAILED OFFICE ACTION

Applicants' amendment filed on 12 August 2009 is acknowledged and entered. Claims 1-14 and 22-24 are cancelled. Claims 15-21 are amended. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 15 and 17, directed to compositions of the allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Claims 16 and 18 remain withdrawn because they are different invention(s) embracing a different scope of using the claimed product, and therefore would require an additional examination and search to resolve issues pertaining to prior art, 35 USC § 112, first paragraph, and 35 USC § 101.

Status of Objections and Rejections:

The rejection of claims 15, 17 and 21 is withdrawn, based on the examiner's amendment herein. Claims 16 and 18-20 remain withdrawn.

Figure 1 is **objected** to for displaying amino acid sequences without the appropriate sequence identifiers. Appropriate correction is *required*.

Examiner's amendments:

Approval for this Examiner's amendment was given by Amy DeCloux on 9 March 2010.

1) Please cancel claims 16 and 18-20.

2) Please replace the claim set with the following rewritten claim set:

Art Unit: 1646

15. (Currently amended) ~~The use of~~ A composition comprising a the binding molecule according to ~~any one of claims 19, 20, and claim 21, as a pharmaceutical and a pharmaceutically acceptable carrier.~~

17. (Currently amended) A composition comprising ~~a~~ the binding molecule according to ~~any one of claims 19, 20, and claim 21, in association with~~ and at least one carrier or diluent.

21. (Currently amended) An isolated human Nogo_A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof, and wherein said heavy chain variable domain or fragment thereof comprises in sequential order SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10; and a light chain variable domain or fragment thereof, and wherein said light chain variable domain or fragment thereof comprises in sequential order SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.

Conclusion:

Claims 15, 17 and 21 are allowed.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (571) 272-0895. The examiner can normally be reached Monday - Friday from 9:00 AM to 5:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Nickol, can be reached at (571) 272-0835.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (in USA or CANADA) or 571-272-1000.

SLW

9 March 2010

/Dong Jiang/
Primary Examiner, Art Unit 1646